CytoMed Therapeutics shares surge 19.91% premarket after securing $500,000 non-dilutive investment for subsidiary LongevityBank from ICH Capital.

CytoMed Therapeutics surged 19.91% in premarket trading following the announcement of a non-dilutive $500,000 investment from ICH Capital for a 10% stake in its subsidiary LongevityBank, which focuses on autologous cell therapies. The funding aligns with the company’s strategic division of efforts: LongevityBank will advance personalized cellular banking services, while CytoMed continues its allogeneic gamma delta T cell therapy development, including an ongoing Phase I trial in Singapore and a Phase II trial in India. Additionally, regulatory developments in China, including a new pathway for cell therapies under State Council Decree No. 818, were cited as opportunities to accelerate commercialization in the region. These updates, combined with partnerships for low-cost manufacturing in China and recent preclinical data on AML treatment, likely drove the sharp premarket rally.